Skip to main content
Clinical Trials/EUCTR2021-005347-79-NL
EUCTR2021-005347-79-NL
Active, not recruiting
Phase 1

The influence of having bariatric surgery on the pharmacokinetics, safety and efficacy of the novel non-nucleoside reverse transcriptase inhibitor doravirine (LABRADOR) - LABRADOR

Radboud University Medical Center0 sites8 target enrollmentFebruary 16, 2022

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
HIV plus bariatric surgery
Sponsor
Radboud University Medical Center
Enrollment
8
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 16, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \-HIV\-infected
  • \-VL suppressed \<40c/ml for at least 6 months, blips are allowed
  • \-planned to have BS (GBP or SG)
  • \-Able to sign informed consent
  • \-Age \> or equal to 18 years
  • \-Using DOR for at least 4 weeks prior to BS with VL \< 40 copies/mL prior to the surgery
  • 7\.Using doravirine for at least 4 weeks prior to bariatric surgery with no detectable viral load
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • \-History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject’s participation
  • \-Requires or is anticipated to require any of the prohibited medications known to contradict/interact with DOR
  • \-Has significant hypersensitivity or other contraindication to DOR
  • \-Creatinine clearance \<40 ml/min
  • \-Severe liver dysfunction (Diagnosed liver cirrhosis: Child\-Pugh C)
  • \-Pregnancy or planning to be pregnant during first 6 months post BS.

Outcomes

Primary Outcomes

Not specified

Similar Trials